89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH; All Dose Groups Achieved Statistically Significant Reductions In Liver Fat, With Relative Reductions Of Up To 60% Versus Baseline And Up To 70% Versus Placebo